SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wordsworth BP, Stedeford J, Rosenberg WM, Bell JI. Limited heterogeneity of the HLA class II contribution to susceptibility to rheumatoid arthritis is suggested by positive associations with HLA-DR4, DR1 and DRw10. Br J Rheumatol 1991; 30: 17880.
  • 2
    Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995; 95: 21206.
  • 3
    Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 86971.
  • 4
    Meyer JM, Evans TI, Small RE, Redford TW, Han J, Singh R, et al. HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. J Rheumatol 1999; 26: 102434.
  • 5
    Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1998; 10: 187200.
  • 6
    Brooks PM. The Heberden Oration 1997: treatment of rheumatoid arthritis: from symptomatic relief to potential cure. Br J Rheumatol 1998; 37: 126571.
  • 7
    Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 30515.
  • 8
    Dayer JM, de Rochemonteix B, Burrus B, Demczuk S, Dinarello CA. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 1986; 77: 6458.
  • 9
    Dinarello CA. The biological properties of interleukin-1. Eur Cytokine Netw 1994; 5: 51731.
  • 10
    Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397440.
  • 11
    Van de Loo AA, Arntz OJ, Bakker AC, van Lent PL, Jacobs MJ, van den Berg WB. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 1995; 146: 23949.
  • 12
    Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen–induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36: 130514.
  • 13
    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196204.
  • 14
    Lubberts E, Joosten LA, Helsen MM, van den Berg WB. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998; 10: 3619.
  • 15
    Miossec P, Briolay J, Dechanet J, Wijdenes J, Martinez-Valdez H, Banchereau J. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum 1992; 35: 87483.
  • 16
    Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40: 210515.
  • 17
    Di Giovine FS, Camp NJ, Cox A, Chaudhary AG, Sorrell JA, Crane A, et al. Detection and population analysis of IL-1 and TNF gene polymorphisms. In: BalkwillF, editor. Cytokine molecular biology. Oxford (UK): Oxford University Press; 2000. p. 2146.
  • 18
    Cox A, Camp NJ, Cannings C, di Giovine FS, Dale M, Worthington J, et al. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999; 8: 170713.
  • 19
    McDowell TL, Symons JA, Ploski R, Førre Ø, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism. Arthritis Rheum 1995; 38: 2218.
  • 20
    Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 13805.
  • 21
    Mansfield JC, Holden H, Tarlow JK, di Giovine FS, McDowell TL, Wilson AG, et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 63742.
  • 22
    Mout R, Willemze R, Landegent JE. Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Res 1991; 19: 3763.
  • 23
    Vandenbroeck K, Martino G, Marrosu M, Consiglio A, Zaffaroni M, Vaccargiu S, et al. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol 1997; 76: 18992.
  • 24
    Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997; 337: 17205.
  • 25
    Guerne PA, Salvi M, Seitz M, Bruhlmann P, Rivier G, Frey D, et al, Swiss Group for Research on HLA in Polymyalgia Rheumatica. Molecular analysis of HLA-DR polymorphism in polymyalgia rheumatica. J Rheumatol 1997; 24: 6716.
  • 26
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 27
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18: 48191.
  • 28
    Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′—3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991; 88: 727680.
  • 29
    Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 74: 82936.
  • 30
    Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 1426.
  • 31
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 32
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al, Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 254250.
  • 33
    Sokka TM, Kaarela K, Mottonen TT, Hannonen PJ. Conventional monotherapy compared to a “sawtooth” treatment strategy in the radiographic progression of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol 1999; 17: 52732.
  • 34
    Bas S, Perneger TV, Mikhnevitch E, Seitz M, Tiercy JM, Roux-Lombard P, et al. Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 10828.
  • 35
    Graudal NA, Jurik AG, de Carvalho A, Graudal HK. Radiographic progression in rheumatoid arthritis: a long-term prospective study of 109 patients. Arthritis Rheum 1998; 41: 147080.
  • 36
    Guasch JF, Bertina RM, Reitsma PH. Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 1996; 8: 598602.
  • 37
    El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398402.
  • 38
    Walley AJ, Cookson WO. Investigation of an interleukin-4 promoter polymorphism for associations with asthma and atopy. J Med Genet 1996; 33: 68992.
  • 39
    Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995; 25 Suppl 2: 748; discussion 95–6.
  • 40
    Cantagrel A, Navaux F, Loubet-Lescoulié P, Nourhashemi F, Enault G, Abbal M, et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42: 1093100.
  • 41
    Buchs N, Silvestri T, di Giovine FS, Chabaud M, Vannier E, Duff GW, et al. IL-4 VNTR gene polymorphism in chronic polyarthritis: The rare allele is associated with protection against destruction. Rheumatology (Oxford) 2000; 39: 112631.